Transcription profiling of yeast grown in gastric or duodenal medium to identify promoters that could be used to down-regulate genes used in the release of therapeutic proteins

ABSTRACT: The use of yeast as a delivery system is an attractive option for the oral administration of therapeutic agents. We recently developed mutants of Saccharomyces cerevisiae capable of lysis upon conditional down-regulation of the expression of the cell wall genes PKC1 and SRB1. The lysis mechanism of the mutant is based on the use of the MET3 promoter, which, upon addition of methionine and cysteine, blocks transcription of SRB1 and PKC1. This strain has the potential to be an integral part of an oral yeast delivery system, in which there is lysis of yeasts in the human gut, followed by release of recombinant proteins for therapeutic use. In order to provide proof-of-principle, the system was evaluated testing the cells viability and lysis performance under conditions, which simulate those f

ORGANISM(S): Saccharomyces cerevisiae

SUBMITTER: Andy Hayes 

PROVIDER: E-MEXP-2127 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress